-
-
-
-
-
-
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
-
-
-
-
-
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
-
-
-
-
-
-
Gilead Sciences shares gain after topping expectations despite lower remdesivir sales
-
-
-
-
-
-
-
Gilead Sciences (GILD) is Trading Near the Value of the HIV Opportunity, Jefferies Sees Good Risk/Reward
-
-
-
-
-
-
-
Gilead Sciences (GILD) Risk Appears Underestimated After Study Data - Jefferies
-
-
-
-
-
-
-
Pre-Open Stock Movers 09/14: (IMMU) (SGMS) (NVDA) Higher; (GILD) (MGM) (WMT) Lower (more...)
-
-
-
-
-
-
-
Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analyst
-
72,062 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

